Compare NXGL & BFRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXGL | BFRG |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | Medical/Dental Instruments | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 9.2M |
| IPO Year | N/A | N/A |
| Metric | NXGL | BFRG |
|---|---|---|
| Price | $0.82 | $0.63 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 203.2K | ★ 237.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.43 |
| 52 Week High | $3.25 | $2.20 |
| Indicator | NXGL | BFRG |
|---|---|---|
| Relative Strength Index (RSI) | 33.55 | 51.61 |
| Support Level | N/A | $0.43 |
| Resistance Level | $2.73 | $0.68 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 19.69 | 52.43 |
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.